Navigation Links
Genova files patent for new prostate cancer treatment
Date:9/8/2009

NEW YORK, Sept. 8 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), is pleased to announce that it has filed a patent for a novel peptide that disrupts the advance of prostate cancer and thus has blockbuster potential as a new anti-cancer drug.

The peptide, called Prostaganin, is a 21-amino compound which is highly reactive to prostate cancer cells, and has the ability to specifically target them. In laboratory experiments, Prostaganin has demonstrated an ability to preferentially bind to and disrupt certain negatively charged components of the membranes of prostate cancer cells.

Prostaganin thus has tremendous potential as a superior new form of treating prostate cancer. Current treatment methods such as surgery, radiation and chemotherapy are outmoded, unsatisfactory, and have severe side effects. Prostaganin offers a positive alternative. The peptide, bio-engineered from naturally occurring compounds in the human body, can target and destroy cancerous cells, whilst leaving surrounding healthy tissues intact, and causing no undesirable side effects. Further development of this novel peptide could revolutionize the way people fight cancer.

The demand for new and better treatments for prostate cancer has never been higher. Prostate cancer presently accounts for 30% of all the major cancers in men. The Prostate Cancer Foundation states that prostate cancer is the cancer with the largest expected increase in the next decade, and that annual incidence of the cancer will rise to 300,000 cases in the U.S. alone by 2015.

"Prostaginin represents a significant milestone in GENova's business agenda to acquire patents for the most innovative new cancer treatments," says Aaron Whiteman, CEO of GENova, "But most importantly, it represents a new generation of cancer treatments that could save millions of lives, and treat prostate cancer in men with no side effects or adverse effects on quality of life. The implications are tremendous." Licensing to companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec could prove to be extremely lucrative in the short and long term. GENova works very hard on a daily basis to close agreements with big Biotechnology players in the industry.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies. Visit GENova online at www.genovabio.comForward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.


'/>"/>
SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. GENova names Dr. John Savin as Vice President
2. GENova names Aaron Whiteman as CEO
3. Sun Pharmaceutical Files HSR Application for Taro Tender Offer
4. InfoLogix Files Preliminary Proxy Statement in Connection with Special Meeting of Its Stockholders to Approve Recapitalization Plan
5. VirtualHealth Technologies Files 8k Related to the August 17th Announcement of Private Access Payment and Document Modification
6. Profiles International Releases New Study Identifying Key Factors for Strategic Workforce Planning
7. "Med Records to Go" Stores Document and Image Files of Medical Facilities for Emergency Viewing
8. AMDL Inc. Files Notification of Late Filing for Form 10-Q
9. Texas Law Firm Files Multiple Suits Against Medtronic as Deadline Approaches
10. Star Scientific Files Second Quarter Financial Results; Rock Creek Pharmaceuticals Reports Early Promising Results in Studies Assessing Safety and Viability of Active Components for a Non-Nicotine Nutraceutical (CigRx(TM))
11. Vitamin Shoppe Files Registration Statement for Initial Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... 2016 , ... Center for Autism and Related Disorders (CARD) Portland today announced ... disorder (ASD) and other developmental disabilities. The group, which is being launched with the ... the opportunity to share stories and advice, seek help, and continue their education on ...
(Date:12/2/2016)... ... 2016 , ... U.S. Surgeon General, Dr. Vivek Murthy, graces the cover of ... was inspired to practice medicine at an early age by his father, who was ... diagnoses and prescribing medicine,” he states. “It is about building relationships with people; relationships ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... two ostomy patients, standing as living proof that attitude and determination can combine ... and issues that spike around the holidays. This campaign will offer patients a ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than half of American teens report losing ... report speaking with their child about sex related topics, less than 60 percent spoke ... proud to announce the launch of its second edition of the “Sexual Wellness” campaign, ...
(Date:12/2/2016)... ... 02, 2016 , ... CloudLIMS.com, a class-leading provider of Laboratory ... CloudLIMS Lite helps biobanks, clinical, research and testing laboratories keep track of their ... version is a faster and a more efficient product, allowing batch processing of ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... -- UCB is pleased to announce that 12 scientific abstracts have ... American Epilepsy Society (AES) Annual Meeting, which takes place ... USA. 1-12 Data being presented include ... ® (lacosamide) CV and BRIVIACT ® (brivaracetam) CV. ... state of the union of epilepsy care and antiepileptic drugs ...
(Date:12/2/2016)... -- Allergan plc (NYSE: AGN ), a leading ... announced Accelerated Share Repurchase (ASR) Program. Logo - ... , ... announced, the Company entered into a variable tenor ASR arrangement ... $10 billion of its ordinary shares. Approximately 40.5 million shares ...
(Date:11/30/2016)... , Nov 30, 2016 Research and ... Intracranial Pressure Monitoring Devices 2017 - MedCore" report to their offering. ... , , ... brain and the skull. In healthy individuals, it is circulated though the ... are cases where the amount of CSF surrounding the brain changes significantly. ...
Breaking Medicine Technology: